The role of the kidney and sodium-glucose cotransporter-2 inhibition in diabetes management

Clinical Diabetes

Volumn 30, Issue 4, 2012, Pages 151-15

  Valentine, Virginia ^a  

^a Northside Family Medicine in Albuquerque   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE TRANSPORTER; INSULIN; IPRAGLIFLOZIN; LX 4211; METFORMIN; PIOGLITAZONE; PLACEBO; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BLOOD LEVEL; BREAST CANCER; COMORBIDITY; DISEASE SEVERITY; DIURESIS; DRUG DOSE REDUCTION; DRUG EFFICACY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MICTURITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSMOTIC DIURESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84871635388     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.30.4.151     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and pre diabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed 30 March 2012
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in obesity among U.S. adults, 1999-2008. JAMA 303:235-241, 2010
3. Goldfine ID, Youngren JF: Contributions of the American Journal of Physiology to the discovery of insulin. Am J Physiol 274:E207-E209, 1998
4. Chao EC, Henry RR: SGLT2 inhibition: a novel strategy for diabetes treatment. Nat Rev Drug Discov 9:551-559, 2010
5. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T: SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104-112, 2011
6. List JF, Whaley JM: Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int 79 (Suppl. 120):S20-S27, 2011
7. McCrimmon RJ, Evans ML, Jacob RJ, Fan X, Zhu Y, Shulman GI, Sherwin RS: AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. Am J Physiol Endocrinol Metab 283:E1076-E1083, 2002
8. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM: Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723-1729, 2008
9. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515, 1987
10. Kohan DE, Fioretto P, List J, Tang W: Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract]. J Am Soc Nephrol 22:232A, 2011
11. Kasichayanula S, Liu X, Benito MP, LaCreta FP, Boulton DW: Influence of renal function on dapagliflozin pharmacodynamics in patients with type 2 diabetes mellitus [abstract]. J Am Soc Nephrol 22:233A, 2011
12. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF: Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217-2224, 2010
13. Wilding JPH, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S: Longterm efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med 156:405-415, 2012
14. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223-2233, 2010
15. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, doubleblind, placebo-controlled trial. Diabetes Obes Metab 13:928-938, 2011
16. Rosenstock J, Vico M, Wei L, Salsali A, List JF: Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:1473-1478, 2012
17. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF: Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66:446-456, 2012
18. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ: Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015-2022, 2011
19. Bailey CJ, Gross JL, Yadav M, Iqbal N, Mansfield TA, List JF: Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone [abstract]. Diabetes 60 (Suppl. 1):A271, 2011
20. Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde AM, Parikh SJ: Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results [abstract]. Diabetes 60 (Suppl. 1A):LB12, 2011
21. Woo V, Tang W, Salsali A, List JF: Long-term efficacy of dapagliflozin monotherapy in patients with type 2 diabetes mellitus [Abstract D-0990]. Presented at the International Diabetes Federation World Diabetes Congress, Dubai, United Arab Emirates, 4-8 December 2011
22. List J, Ley S, Ptaszynska A, Johnsson KM, Schmitz BG, Sugg JE, Parikh SJ: Characterization of genital infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes 60 (Suppl. 1):A270, 2011
23. Parikh SJ, Johnsson KM, Ptaszynska A, Schmitz BG, Sugg JE, List JF: Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes 60 (Suppl. 1):A270, 2011
24. Jones D: Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 10:645-646, 2011
25. Inagaki N, Kondo K, Iwasaki T, Maruyama N, Susuta Y, Sakai S, Kuki H: Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM) [abstract]. Diabetes 60 (Suppl. 1):A274, 2011
26. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W, for the Canagliflozin DIA 2001 Study Group: Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:1232-1238, 2012
27. Ferrannini E, Seman LJ, Seewaldt- Becker E, Hantel S, Pinnetti S, Woerle HJ: The potent and highly selective sodiumglucose co-transporter (SGLT-2) inhibitor BI10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus [abstract]. Diabetologia 53:S351, 2010
28. Rosenstock J, Jelaska A, Seman L, Pinnetti S, Hantel S, Woerle HJ: Efficacy and safety of BI 10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin [abstract]. Diabetes 60 (Suppl. 1):A271, 2011
29. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S: ASP1941, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes [abstract]. Diabetes 59 (Suppl. 1):75-OR, 2010
30. Freiman J, Ruff DA, Frazier KS, Combs K, Turnage A, Shadoan M, Powell D, Zambrowicz B, Brown P: LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvement in glycemic control over 28 days in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 59 (Suppl. 1A):LB5, 2010
31. Nucci G, Amin NB, Wang X, Lee DS, Rusnak JM: The sodium glucose co-transporter- 2 (SGLT2) inhibitor, PF04971729, provides multi-faceted improvements in diabetic patients inadequately controlled on metformin [abstract]. Diabetologia 54: S347, 2011
32. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovic L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL; AACE Task Force for Developing Diabetes Comprehensive Care Plan: American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract 17:287-302, 2011
33. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: an algorithm for glycemic control. Endocr Pract 15:540-559, 2009
34. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M: Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 12:510-516, 2010
35. Rosenstock J, Polodori D, Zhao Y, Sha S, Arbit D, Usiskin K, Capuano G, Canovatchel W: Canagliflozin, an inhibitorof sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin [abstract]. Diabetologia 53:S349, 2010
36. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97:1020-1031, 2012
37. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB: Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867-1872, 2002
38. Amin NB, Wang X, Nucci G, Rusnak JM: The sodium glucose co-transporter-2(SGLT2) inhibitor, PF04971729, yielded BP lowering in hypertensive patients with type 2 diabetes mellitus (T2DM) [abstract]. Diabetes 60 (Suppl. 1A):LB14, 2011
39. U.K. Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2diabetes: UKPDS 38. BMJ 317:703-713, 1998
40. You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK, Hediger MA: Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270:29365-29371, 1995